Rare Disease Intelligence
Strategic coverage of orphan drug development, regulatory reform and competitive landscape dynamics.
Next-Generation MS Therapy Competition: BTK Inhibitors Are Reshaping the Landscape
May 25, 2026
BTK inhibitors are rapidly emerging as a transformative therapeutic class in multiple sclerosis, shifting treatment focus from relapse control toward neurodegeneration and CNS-targeted immune modulation.
FDA Officially Approves Saphnelo Auto-Injector: SLE Patients May Soon Say Goodbye to Long Infusion Sessions
May 21, 2026
The FDA has officially approved the Saphnelo auto-injector for self-administration, marking a new era of home-based treatment and long-term management for SLE patients.
New Advances in Gaucher Disease Classification: Clinical Characteristics of Type I, Type II, Type III, and Rare Subtypes
May 11, 2026
Recurrent Respiratory Infections with Malnutrition and Growth Delay — Beware of the Rare Pediatric Disease: Cystic Fibrosis (CF)
May 08, 2026
Learn about cystic fibrosis (CF), a rare inherited pediatric disease characterized by recurrent respiratory infections, malnutrition, growth delay, and CFTR gene mutations.
Targeting TL1A in Immune-Mediated Inflammatory Diseases: From an Inflammatory Amplifier to a New Strategy for Precision Intervention
April 30, 2026
World’s First! In Vivo CAR-T Successfully Treats Systemic Lupus Erythematosus: A Revolutionary Breakthrough in Immune Reprogramming
April 28, 2026
In vivo CAR-T shows breakthrough potential in systemic lupus erythematosus, marking a new era of immune system reprogramming.
Covering Nearly 20 Rare Diseases: A Comprehensive Overview of Newly Approved Rare Disease Drugs Worldwide in March 2026
April 16, 2026
A comprehensive review of nearly 20 newly approved rare disease drugs worldwide in March 2026, covering hematology, oncology, metabolic disorders, and gene therapy.
2026 Global Innovative Drug R&D and Regulatory Dynamics: ADC and Gene Therapies Lead a New Era
April 10, 2026
In 2026, global innovative drug R&D continues to accelerate, with Antibody-Drug Conjugates (ADCs) and gene therapies taking center stage. This article deeply analyzes the latest approval dynamics from the FDA and NMPA, and explores how these cutting-edge technologies are reshaping the landscape of oncology and rare disease treatments.
Global Pharmaceutical Innovation and Regulatory Dynamics in 2026: Breakthroughs in Oncology and Rare Diseases
April 09, 2026
Global Access to Thalassemia Gene Therapy in 2026: USA vs Europe vs China
April 08, 2026
Where can patients access thalassemia gene therapy? Compare the United States, Europe, and China in terms of cost, availability, and clinical access.
CRISPR Gene Therapy Enters the Clinical Era: Casgevy Approval Marks the Dawn of Gene Editing Treatments
April 03, 2026
The approval of Casgevy, the world’s first CRISPR-based therapy, marks a historic milestone in medicine, transitioning gene editing from lab research to life-changing clinical treatment.
FGFR Inhibitors: Emerging Targeted Therapies for Rare Skeletal Disorders
March 23, 2026
New Breakthroughs in Clinical Research on Paroxysmal Nocturnal Hemoglobinuria (PNH) from a Global Perspective
March 18, 2026
The Rise of China’s Rare Disease Drugs: From Follower to Emerging Global Leader
February 27, 2026
China’s rare disease drug industry is transitioning from generics-based participation to innovation-driven global competitiveness, supported by regulatory reform, biotechnology advancement, cost efficiency, and industrial integration.
Why Humanity Continues to Invest in Orphan Drug Research — Despite Only 5% of Rare Diseases Being Treatable
February 27, 2026
Only 5% of rare diseases have approved treatments. Yet global investment in orphan drug research continues to grow. This article examines the scientific, ethical, and systemic drivers behind sustained rare disease innovation.